2026-10-29
$12M of new funding is targeting healthcare revenue cycle and prior authorization
2 funded companies building into healthcare revenue cycle and prior authorization. The work in scope is what the VP Revenue Cycle owns today.
The funding
See which development path to back before you commit. Atlas runs in silico clinical trials in immunology using its foundation AI model of human biology to predict and compare patient responses across treatments and indications, helping biopharma teams decide what to advance, acquire or expand.
Atlas Bio Raises $12.5M to Tackle Phase II Failure [2026] →Hemas Hospital Wattala Raises the Benchmark for Breast Care in Sri Lanka at Landmark Clinical Symposium
Hemas Hospital Wattala Raises the Benchmark for Breast Care in Sri Lanka at Landmark Clinical Symposium →What it means
Capital arriving in a function is a reliable leading indicator. It does not mean the incumbents are wrong, and it does not mean these companies will succeed. It means that within the next few quarters the people who run this work will be asked what their function is doing about it, and the honest answer has to start with where that function actually stands.
So we built the assessment for it. Not a purchase decision, a structured set of questions to take to your own team.